U.S. markets closed

TELA Bio, Inc. (TELA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
8.38-0.47 (-5.31%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected


Previous Close8.85
Bid3.53 x 1000
Ask13.97 x 800
Day's Range8.38 - 9.02
52 Week Range7.23 - 16.53
Avg. Volume25,772
Market Cap121.993M
Beta (5Y Monthly)1.57
PE Ratio (TTM)N/A
EPS (TTM)-2.49
Earnings DateAug 09, 2022 - Aug 15, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.25
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for TELA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • TELA Bio, Inc.
    Daily – Vickers Top Buyers & Sellers for 11/09/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    6 months agoArgus Research
View more
  • Simply Wall St.

    The past year for TELA Bio (NASDAQ:TELA) investors has not been profitable

    Investors can approximate the average market return by buying an index fund. When you buy individual stocks, you can...

  • Zacks

    TELA Bio, Inc. (TELA) Reports Q1 Loss, Tops Revenue Estimates

    TELA Bio, Inc. (TELA) delivered earnings and revenue surprises of -50% and 4.19%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    TELA Bio Reports First Quarter 2022 Financial Results

    MALVERN, Pa., May 10, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today reported financial results for the first quarter ended March 31, 2022. Recent Highlights Reported revenue of $8.2 million for the first quarter, representing growth of 40% over the corresponding p